Migraine drug NURTEC under Real-World safety watch in korea
NCT ID NCT07497854
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will monitor the safety and effectiveness of NURTEC ODT 75 mg (rimegepant) in 3000 Korean adults with migraine. Participants will take the drug as prescribed for acute attacks or prevention. Researchers will track side effects and how well the drug works, including pain relief within 2 hours and changes in monthly migraine days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rimegepant sulfate (NURTEC ODT 75 mg)
What this could lead to
If successful, this study could confirm that NURTEC is a safe and effective option for both stopping migraine attacks and preventing them in Korean patients.
What could go wrong
This is a post-marketing surveillance study, not a new treatment discovery. It primarily monitors safety in a real-world setting, so no breakthrough is expected. Results may not apply outside Korea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE WITH OR WITHOUT AURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••